Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and Cancer of Colon

gefitinib has been researched along with Cancer of Colon in 43 studies

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's21 (48.84)29.6817
2010's21 (48.84)24.3611
2020's1 (2.33)2.80

Authors

AuthorsStudies
Chen, L; He, L; Liu, Y; Ma, L; Nie, C; Pu, Y; Shao, M; Wang, F; Wu, W; Wu, Y; Yang, Z; Yu, K1
Jia, J; Niu, X; Song, Q; Sun, L; Wang, L; Zhang, H; Zhang, Y; Zhang, Z; Zhao, H; Zheng, C1
Ahmed, RA; Al-Bratty, M; Al-Kasim, MA; Alhazmi, HA; Ali, R; Attafi, IM; Intakhab Alam, M; Makeen, HA; Mohan, S; Safhi, MM; Sultan, MH; Syed, NK1
Choo, J; Chung, HY; Heo, G; Im, E; Jung, JH; Jung, Y; Kim, DH; Kim, MJ; Kim, SJ; Kim, W; Lee, Y; Moon, HR; Noh, TH; Son, S1
Funato, Y; Hasegawa, A; Miki, H; Mori, MX; Mori, Y; Sato, T; Tran, HN; Yamazaki, D1
He, K; Yu, J; Zhang, L; Zheng, X1
Brewer, M; Janakiram, NB; Mohammed, A; Rao, CV; Steele, VE; Vedala, K1
Chen, PJ; Huang, GB; Li, B; Lou, YF; Luo, XY; Yu, XR; Zheng, DQ; Zou, ZZ1
Asbagh, LA; Baietti, MF; Budinska, E; De Vriendt, V; Hoe, N; Imjeti, NS; Jacobs, B; Sablina, A; Singh, S; Steklov, M; Tejpar, S; Vazquez, I; Vecchione, L; Zimmermann, P1
Hua, X; Jin, J; Katona, BW; Liu, Y; Ma, A1
Ashinuma, H; Sekine, I1
Watanabe, A1
Chen, L; Cheng, H; Guo, X; Meng, Y; Sheng, X; Tai, G; Zhang, F; Zhou, Y1
Cui, Y; He, Y; Liu, M; Ma, H; Qiu, P; Tang, Y; Wang, S; Xu, H; Xu, L; Zeng, X; Zhang, L; Zhang, M1
Castellani, G; Ceccarelli, C; Coppola, D; Francesconi, M; Guidotti, L; Lauriola, M; Martini, D; Mattei, G; Montroni, I; Pezzetti, F; Rosati, G; Ruggeri, A; Santini, D; Solmi, R; Strippoli, P; Taffurelli, M; Ugolini, G; Voltattorni, M; Zanotti, S1
Antonacopoulou, A; Floratou, K; Giannopoulou, E; Kalofonos, HP; Papavassiliou, AG1
Funato, T; Takeda, M1
Chang, JG; Feng, YH; Lee, JC; Lu, PJ; Shiau, AL; Shieh, GS; Tsao, CJ; Wu, CL; Yeh, KT1
Soyibo, AK; Whittle, DO1
He, F; Huang, L; Wang, F; Yang, L1
Bae, JH; Chung, JS; Kang, CD; Kim, MJ; Kim, SH; Kim, SJ; Oh, SO1
Jin, YB; Ko, YG; Lee, JS; Lee, M; Lee, YJ; Lee, YS; Park, JJ; Yi, JY1
Dai, X; Du, Y; Feng, Y; Li, X; Liu, J; Wang, H; Xia, L; Zhang, J1
Bai, YX; Bian, WX; Han, Y; Liu, L; Yuan, HH1
Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Tortora, G; Troiani, T; Veneziani, BM; Zangemeister-Wittke, U1
Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Mareel, M; May, FE; Nguyen, QD; Rodrigue, CM; Rodrigues, S; Thim, L; Westley, BR1
Azzariti, A; Colucci, G; Paradiso, A; Xu, JM1
Azzariti, A; Paradiso, A; Porcelli, L; Xu, JM1
Dimitroulakos, J; Goss, G; Hanson, JE; Lagarde, AE; Lorimer, IA; Mantha, AJ1
Lindner, H; Loeffler-Ragg, J; Mueller, D; Sarg, B; Skvortsov, S; Skvortsova, I; Witsch-Baumgartner, M; Zwierzina, H1
Goldstein, D; Qu, XJ; Russell, PJ; Yang, JL1
Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M1
Braun, AH; Dirsch, O; Hilger, RA; Seeber, S; Stark, K; Vanhoefer, U1
Bartralot, R; Bodet, D; García-Patos, V; Heras, C; Mollet, J1
Borner, MM1
Barrow, D; Gee, JM; Holloway, B; Jones, HE; Nicholson, RI; Tonge, D1
Azzariti, A; Paradiso, A; Porcelli, L; Simone, GM; Xu, JM1
Bissonnette, M; Cerda, S; Cohen, G; Dougherty, U; Fichera, A; Gong, C; Hart, J; Jagadeeswaran, S; Joseph, L; Khare, S; Little, N; Mustafi, R; Sehdev, A; Tallerico, M; Tretiakova, M; Turner, JR; Yuan, W1
Azzariti, A; Han, Y; Li, YM; Li, ZQ; Paradiso, A; Wang, Y; Xu, JM; Yang, WW; Yuan, SJ; Zhao, CH1
Aluri, L; Bissonnette, M; Cerda, S; Chumsangsri, A; Cohen, EE; Delgado, J; Dougherty, U; Fichera, A; Hart, J; Jagadeeswaran, S; Joseph, L; Little, N; Mustafi, R; Sehdev, A; Tretiakova, M; Yuan, W1
Hirakawa, K; Inoue, H; Mimori, K; Mori, M; Nagahara, H; Ohira, M; Sawada, T; Zhang, X1
Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM; Zunino, F1
Dubreuil, A; Fischel, JL; Formento, P; Laurent-Puig, P; Magné, N; Milano, G; Poupon, MF1

Reviews

3 review(s) available for gefitinib and Cancer of Colon

ArticleYear
[Companion Diagnostics for Solid Tumors].
    Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:11

    Topics: Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Crizotinib; Diagnostic Uses of Chemicals; Drug Discovery; ErbB Receptors; Gefitinib; Gene Fusion; Guidelines as Topic; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Pharmacogenetics; Precision Medicine; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Trastuzumab

2015
[Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests].
    Rinsho byori. The Japanese journal of clinical pathology, 2010, Volume: 58, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cetuximab; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genes, ras; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Mutation; Pharmacogenetics; Quality Control; Quinazolines

2010
[Molecular targets in colon cancer].
    Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4

    Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib

2006

Other Studies

40 other study(ies) available for gefitinib and Cancer of Colon

ArticleYear
Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
    Bioorganic & medicinal chemistry, 2015, Jul-01, Volume: 23, Issue:13

    Topics: Angiogenesis Inhibitors; Animals; Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Cell Line, Tumor; Cell Movement; Colchicine; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Protein Binding; Stilbenes; Structure-Activity Relationship; Thiazoles; Tubulin Modulators; Xenograft Model Antitumor Assays

2015
An oral drug delivery system with programmed drug release and imaging properties for orthotopic colon cancer therapy.
    Nanoscale, 2019, Aug-29, Volume: 11, Issue:34

    Topics: Acrylic Resins; Administration, Oral; Animals; Chitosan; Colonic Neoplasms; Contrast Media; Delayed-Action Preparations; Durapatite; Fluorouracil; Gadolinium; Gefitinib; HT29 Cells; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles

2019
Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity
    Drug delivery, 2020, Volume: 27, Issue:1

    Topics: Antineoplastic Agents; Cell Death; Colonic Neoplasms; Drug Carriers; Drug Delivery Systems; Drug Liberation; Gefitinib; HCT116 Cells; Humans; Lipids; Nanostructures; Particle Size

2020
Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer.
    Cell death & disease, 2018, 08-29, Volume: 9, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genes, src; HCT116 Cells; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Signal Transduction; src-Family Kinases

2018
Cnnm4 deficiency suppresses Ca
    Oncogene, 2019, Volume: 38, Issue:20

    Topics: Animals; Calcium Signaling; Cation Transport Proteins; Cell Proliferation; Colon; Colonic Neoplasms; Epidermal Growth Factor; Epithelium; Female; Gefitinib; Magnesium; Male; Mice, Mutant Strains; Organ Culture Techniques; TRPV Cation Channels

2019
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Crizotinib; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2013
Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis.
    Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:5

    Topics: Adenomatous Polyps; Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinogenesis; Cell Proliferation; Chemoprevention; Colon; Colonic Neoplasms; Cytokines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Eflornithine; Female; Gefitinib; Heptanoic Acids; Intestine, Small; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Pyrroles; Quinazolines

2013
Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases

2014
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
    Oncotarget, 2014, Oct-30, Volume: 5, Issue:20

    Topics: Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; HT29 Cells; Humans; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; RNA, Messenger; Signal Transduction; src-Family Kinases

2014
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
    Cancer biology & therapy, 2014, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; ErbB Receptors; Gefitinib; Gene Expression; Humans; Phosphorylation; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering

2014
[Targeted therapy for solid tumors in the elderly].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8

    Topics: Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Trastuzumab

2015
Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation.
    Apoptosis : an international journal on programmed cell death, 2016, Volume: 21, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Colonic Neoplasms; Gefitinib; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Quinazolines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation

2016
Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells.
    BMC cancer, 2017, 01-13, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines

2017
Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.
    BMC cancer, 2008, Aug-08, Volume: 8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Cluster Analysis; Colonic Neoplasms; Epidermal Growth Factor; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microscopy, Electron, Scanning; Microvilli; Oligonucleotide Array Sequence Analysis; Quinazolines

2008
Dual targeting of EGFR and HER-2 in colon cancer cell lines.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab

2009
Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.
    Cancer science, 2010, Volume: 101, Issue:9

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Survival; Cetuximab; Colonic Neoplasms; ErbB Receptors; Female; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays

2010
Colorectal cancer.
    The West Indian medical journal, 2011, Volume: 60, Issue:2

    Topics: Antineoplastic Agents; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genetic Therapy; Humans; Interferon-alpha; Quinazolines

2011
The effect of combining interferon-alpha and gefitinib in human colon cancer cell lines.
    The West Indian medical journal, 2011, Volume: 60, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Quinazolines

2011
Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
    Cancer science, 2012, Volume: 103, Issue:1

    Topics: Blotting, Western; Chromatin Immunoprecipitation; Colonic Neoplasms; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; GPI-Linked Proteins; Humans; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation

2012
Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
    Biochemical pharmacology, 2012, Apr-01, Volume: 83, Issue:7

    Topics: Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; HT29 Cells; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Mice; Mice, Nude; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sialic Acids; Sialyltransferases; Transfection; Xenograft Model Antitumor Assays

2012
EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis.
    Cell proliferation, 2012, Volume: 45, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Quinazolines; Signal Transduction

2012
The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines.
    Pathology, 2012, Volume: 44, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colonic Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Quinazolines

2012
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Death; Cell Division; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligonucleotides; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003
Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells.
    Oncogene, 2003, Jul-17, Volume: 22, Issue:29

    Topics: Amphiregulin; Animals; Cells, Cultured; Colonic Neoplasms; Dogs; EGF Family of Proteins; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, src; Glycoproteins; Growth Substances; Humans; Intercellular Signaling Peptides and Proteins; Kidney; Mucins; Muscle Proteins; Mutation; Neoplasm Invasiveness; Neuropeptides; Peptides; Phosphatidylinositol 3-Kinases; Proteins; Quinazolines; Receptors, Thromboxane; Signal Transduction; Transforming Growth Factor alpha; Trefoil Factor-1; Trefoil Factor-2; Trefoil Factor-3; Tumor Suppressor Proteins

2003
The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Adducts; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gefitinib; HT29 Cells; Humans; Inhibitory Concentration 50; Organoplatinum Compounds; Oxaliplatin; Precipitin Tests; Quinazolines

2003
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
    Biochemical pharmacology, 2004, Jul-01, Volume: 68, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Irinotecan; Quinazolines; Signal Transduction; Tumor Cells, Cultured

2004
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6

    Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured

2005
Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:15

    Topics: Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; Humans; Protein Kinase Inhibitors; Proteome; Quinazolines; Receptor, ErbB-3

2005
Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines.
    Oncology, 2005, Volume: 69, Issue:3

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Interferon-alpha; Quinazolines; Time Factors; Up-Regulation

2005
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 50, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms

2005
The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
    Anti-cancer drugs, 2005, Volume: 16, Issue:10

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin E; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2005
[Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
    Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:2

    Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease Susceptibility; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Proteins; Quinazolines; Staphylococcal Skin Infections; Superinfection

2006
Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.
    British journal of cancer, 2006, Jul-17, Volume: 95, Issue:2

    Topics: Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Diphosphonates; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin; Insulin-Like Growth Factor II; Phosphorylation; Protein Isoforms; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured

2006
Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.
    World journal of gastroenterology, 2006, Aug-28, Volume: 12, Issue:32

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Piperidines; Quinazolines; Signal Transduction; Time Factors

2006
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.
    Cancer research, 2007, Jan-15, Volume: 67, Issue:2

    Topics: Adenoma; Animals; Azoxymethane; beta Catenin; Carcinogens; Cell Transformation, Neoplastic; Colonic Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, ras; Male; Mice; Mice, Inbred A; Mutation; Quinazolines; Signal Transduction; Up-Regulation

2007
[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction

2006
Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Apr-15, Volume: 14, Issue:8

    Topics: Animals; Azoxymethane; CCAAT-Enhancer-Binding Protein-beta; Colonic Neoplasms; Cyclin D; Cyclins; Disease Progression; ErbB Receptors; Gefitinib; Male; Precancerous Conditions; Quinazolines; Rats; Rats, Inbred F344; STAT3 Transcription Factor; Transcription Factor AP-1

2008
Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib.
    Oncology reports, 2008, Volume: 19, Issue:6

    Topics: Antineoplastic Agents; Blotting, Western; Colonic Neoplasms; Disease Susceptibility; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Mutagenesis, Site-Directed; Mutation; Quinazolines; Tumor Cells, Cultured

2008
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligodeoxyribonucleotides, Antisense; Ovarian Neoplasms; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2001
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
    British journal of cancer, 2002, May-06, Volume: 86, Issue:9

    Topics: Antineoplastic Agents; Blotting, Western; Colonic Neoplasms; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2002